https://www.selleckchem.com/products/Axitinib.html
Eleven patients (21%) showed no evidence of extracranial disease. Forty-four patients (85%) had clinical symptoms at LMD diagnosis. Forty-two patients (81%) had received at least one prior therapy. Forty patients (77%) received at least one treatment after LMD diagnosis, including TT (n=17), ICB (n=13), bevacizumab (n=1), radiotherapy (n=3), and intrathecal chemotherapy (n=1); five patients received both TT and ICB. Twelve patients (23%) received no treatment because of rapid progression of LMD. The median OS for the entire cohort was
Like
Comment
Share
